Share this article
NEW YORK, June 1, 2021 /PRNewswire/ Eucrates Biomedical Acquisition Corp. (Nasdaq: EUCR) (the
Company ), a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, today announced that it received a notice (
Notice ) from the Listing Qualifications Department of The Nasdaq Stock Market (
Nasdaq ) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the
Rule ) because the Company failed to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the
Form 10-Q ) with the Securities and Exchange Commission (
Best SPAC Opportunities for Monday
With the SPAC market slowing down and starting to clear out, some investors are looking for upside with announced deals. In addition, investors continue to look in the bargain bin for yield as well.
Author:
Apr 5, 2021
Last week we saw the SPAC IPO market close for business with only 2 SPACs pricing. This is good news as the market needs to clear out so that investors can get excited again about good SPACs and good deals. Given that there has been no IPO pop and very little deal announcement pop lately though CMII and AJAX had a some SPAC investors are starting to look at a combination of strong sponsor/teams with SPACs that already have announced deals.
SPAC Weekly Wrap: Stock Issuance Grinds to a Halt. Time for Deals
In a dramatic reversal of the last few months, the SPAC IPO market essentially closed this week as only 2 IPOs priced and just a handful of new S-1s.
Author:
Apr 2, 2021
The week ends on a quiet note as the stock market was closed for Good Friday. Looking back, this week might be remembered as the moment when the SPAC market exuberance finally caught up to itself, and the market really cooled off. All this week we ve been noting how issuance has slowed and SPACs are routinely trading weaker.
Search jobs Eucrates Biomedical Acquisition Corp. Announces The Separate Trading Of Its Ordinary Shares And Redeemable Warrants
NEW YORK, Dec. 14, 2020 /PRNewswire/ Eucrates Biomedical Acquisition Corp. (the Company ), a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, today announced that holders of the units sold in the Company s initial public offering of 10,000,000 units, may elect to separately trade the ordinary shares and redeemable warrants included in the units. Those units not separated will continue to trade on The Nasdaq Capital Market ( Nasdaq ) under the symbol EUCRU, and the ordinary shares and redeemable warrants that are separated will trade on the Nasdaq under the symbols EUCR and EUCRW, respectively. No fractional warrants will be issued upon separation of the units and
Eucrates Biomedical Acquisition Corp Announces The Separate Trading Of Its Ordinary Shares And Redeemable Warrants cnweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cnweekly.com Daily Mail and Mail on Sunday newspapers.